497 related articles for article (PubMed ID: 29733441)
1. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
[TBL] [Abstract][Full Text] [Related]
2. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
3. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
Saag KG; Fitz-Patrick D; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; Becker MA
Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
[TBL] [Abstract][Full Text] [Related]
5. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
6. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
Perez-Ruiz F; Sundy JS; Miner JN; Cravets M; Storgard C;
Ann Rheum Dis; 2016 Jun; 75(6):1074-80. PubMed ID: 26742777
[TBL] [Abstract][Full Text] [Related]
7. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
Dalbeth N; Jones G; Terkeltaub R; Khanna D; Kopicko J; Bhakta N; Adler S; Fung M; Storgard C; Baumgartner S; Perez-Ruiz F
Arthritis Rheumatol; 2017 Sep; 69(9):1903-1913. PubMed ID: 28597604
[TBL] [Abstract][Full Text] [Related]
8. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.
Alghamdi YS; Soliman MM; Nassan MA
BMC Pharmacol Toxicol; 2020 Feb; 21(1):10. PubMed ID: 32041665
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
[TBL] [Abstract][Full Text] [Related]
12. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
[TBL] [Abstract][Full Text] [Related]
13. New urate-lowing therapies.
Abhishek A
Curr Opin Rheumatol; 2018 Mar; 30(2):177-182. PubMed ID: 29251661
[TBL] [Abstract][Full Text] [Related]
14. Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia.
JAMA; 2018 Jan; 319(2):188-189. PubMed ID: 29318274
[No Abstract] [Full Text] [Related]
15. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Presa M; Pérez-Ruiz F; Oyagüez I
Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
[TBL] [Abstract][Full Text] [Related]
16. Lesinurad for the treatment of hyperuricaemia in people with gout.
Robinson PC; Dalbeth N
Expert Opin Pharmacother; 2017 Dec; 18(17):1875-1881. PubMed ID: 29103339
[TBL] [Abstract][Full Text] [Related]
17. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
[TBL] [Abstract][Full Text] [Related]
18. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
[No Abstract] [Full Text] [Related]
19. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
[TBL] [Abstract][Full Text] [Related]
20. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
Tausche AK; Alten R; Dalbeth N; Kopicko J; Fung M; Adler S; Bhakta N; Storgard C; Baumgartner S; Saag K
Rheumatology (Oxford); 2017 Dec; 56(12):2170-2178. PubMed ID: 29029210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
